Items where authors include "Nguyen-Van-Tam, J.S."

Article

Abhishek, A. orcid.org/0000-0003-0121-4919, Peckham, N. orcid.org/0000-0003-1066-0726, Pade, C. orcid.org/0000-0003-0626-2346 et al. (22 more authors) (2025) Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT. Efficacy and Mechanism Evaluation. ISSN 2050-4365

Abhishek, A., Peckham, N., Pade, C. et al. (65 more authors) (2024) Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6 (2). e92-e104. ISSN 2665-9913

Standing, J.F. orcid.org/0000-0002-4561-7173, Buggiotti, L. orcid.org/0000-0002-7404-7800, Guerra-Assuncao, J.A. et al. (50 more authors) (2024) Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients. Nature Communications, 15 (1). 1652. ISSN 2041-1723

Shaw, R.H., Greenland, M., Stuart, A.S.V. et al. (37 more authors) (2023) Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, 86 (6). pp. 574-583. ISSN 0163-4453

Shaw, R.H., Liu, X., Stuart, A.S.V. et al. (81 more authors) (2022) Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine, 10 (11). pp. 1049-1060. ISSN 2213-2600

Killingley, B., Mann, A.J., Kalinova, M. et al. (28 more authors) (2022) Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 28 (5). pp. 1031-1041. ISSN 1078-8956

Stuart, A.S.V., Shaw, R.H., Liu, X. et al. (40 more authors) (2022) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, 399 (10319). pp. 36-49. ISSN 0140-6736

Preprint

Killingley, B., Mann, A., Kalinova, M. et al. (28 more authors) (2022) Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge. [Preprint]